Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: A possible role of SGLT2 in mesangial cells
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: A possible role of SGLT2 in mesangial cells ; volume:9 ; number:1 ; day:18 ; month:3 ; year:2019 ; pages:1-8 ; date:12.2019
Scientific reports ; 9, Heft 1 (18.3.2019), 1-8, 12.2019
- Klassifikation
-
Naturwissenschaften
- Urheber
-
Maki, Toshinobu
Maeno, Sayaka
Maeda, Yasutaka
Yamato, Mayumi
Sonoda, Noriyuki
Ogawa, Yoshihiro
Wakisaka, Masanori
Inoguchi, Toyoshi
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-019-41253-7
- URN
-
urn:nbn:de:101:1-2019040701420693551943
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:52 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Maki, Toshinobu
- Maeno, Sayaka
- Maeda, Yasutaka
- Yamato, Mayumi
- Sonoda, Noriyuki
- Ogawa, Yoshihiro
- Wakisaka, Masanori
- Inoguchi, Toyoshi
- SpringerLink (Online service)
Ähnliche Objekte (12)
SGLT2 and cancer
Direct cardiac effects of SGLT2 inhibitors
Targeting high glucose-induced epigenetic modifications at cardiac level: the role of SGLT2 and SGLT2 inhibitors
Class effects of SGLT2 inhibitors on cardiorenal outcomes
The potential anti-arrhythmic effect of SGLT2 inhibitors
Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice
SGLT2-Hemmer : Geringere Mortalität und Nierenschutz
Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation
A Fluorescent Glucose Transport Assay for Screening SGLT2 Inhibitors in Endogenous SGLT2-Expressing HK-2 Cells
Use of Animal Models for Investigating Cardioprotective Roles of SGLT2 Inhibitors
Is GFR decline induced by SGLT2 inhibitor of clinical importance?
Comparison of incident hypertension between SGLT2 inhibitors vs. DPP4 inhibitors
SGLT2 and cancer
Direct cardiac effects of SGLT2 inhibitors
Targeting high glucose-induced epigenetic modifications at cardiac level: the role of SGLT2 and SGLT2 inhibitors
Class effects of SGLT2 inhibitors on cardiorenal outcomes
The potential anti-arrhythmic effect of SGLT2 inhibitors
Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice
SGLT2-Hemmer : Geringere Mortalität und Nierenschutz
Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation
A Fluorescent Glucose Transport Assay for Screening SGLT2 Inhibitors in Endogenous SGLT2-Expressing HK-2 Cells
Use of Animal Models for Investigating Cardioprotective Roles of SGLT2 Inhibitors
Is GFR decline induced by SGLT2 inhibitor of clinical importance?
Comparison of incident hypertension between SGLT2 inhibitors vs. DPP4 inhibitors
SGLT2 and cancer
Direct cardiac effects of SGLT2 inhibitors
Targeting high glucose-induced epigenetic modifications at cardiac level: the role of SGLT2 and SGLT2 inhibitors
Class effects of SGLT2 inhibitors on cardiorenal outcomes
The potential anti-arrhythmic effect of SGLT2 inhibitors
Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice
SGLT2-Hemmer : Geringere Mortalität und Nierenschutz
Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation
A Fluorescent Glucose Transport Assay for Screening SGLT2 Inhibitors in Endogenous SGLT2-Expressing HK-2 Cells
Use of Animal Models for Investigating Cardioprotective Roles of SGLT2 Inhibitors
Is GFR decline induced by SGLT2 inhibitor of clinical importance?